Growth Metrics

Caribou Biosciences (CRBU) Depreciation & Amortization (CF) (2020 - 2025)

Caribou Biosciences has reported Depreciation & Amortization (CF) over the past 6 years, most recently at $682000.0 for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 42.4% to $682000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, down 7.18% year-over-year, with the annual reading at $3.6 million for FY2025, 7.18% down from the prior year.
  • Depreciation & Amortization (CF) was $682000.0 for Q4 2025 at Caribou Biosciences, up from $631000.0 in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $1.6 million in Q3 2023 and troughed at $221000.0 in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $624000.0 (2023), against an average of $685150.0.
  • Year-over-year, Depreciation & Amortization (CF) skyrocketed 250.89% in 2023 and then tumbled 46.39% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $273000.0 in 2021, then surged by 85.35% to $506000.0 in 2022, then soared by 46.25% to $740000.0 in 2023, then surged by 60.0% to $1.2 million in 2024, then crashed by 42.4% to $682000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Depreciation & Amortization (CF) are $682000.0 (Q4 2025), $631000.0 (Q3 2025), and $1.2 million (Q2 2025).